The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray

Sativex is a cannabis-based medicine that comes in the form of an oromucosal spray. It contains equal amounts of Δ9-tetrahydrocannabinol and cannabidiol, two compounds derived from cannabis plants. Sativex has been shown to have positive effects on symptoms of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and sleep disorders. It also has analgesic, antiinflammatory, antitumoral, and neuroprotective properties, which make it a potential treatment option for other neurological disorders. The article reviews the results of recent preclinical and clinical studies that support the therapeutic potential of Sativex and the molecular mechanisms behind its neuroprotective benefits in various neurological disorders. The article also discusses the possible advantages and disadvantages of using Sativex as a neurotherapeutic agent, such as its safety, efficacy, availability, and legal status.

Enhancing Efficacy, Performance, and Reliability of Cannabis Edibles: Insights from Lipid Bioavailability Studies

The legal sale of cannabis-enriched foods and beverages for medical or recreational purposes is increasing in many states and countries, especially in North America and Europe. These food-based cannabis delivery systems vary considerably in their compositions and structures, ranging from low-viscosity watery beverages to solid fatty chocolates. The rate and extent of release of the bioactive components in cannabis within the human gastrointestinal tract (GIT) affect their health and psychoactive effects. Studies with other types of hydrophobic bioactives, such as nutraceuticals and vitamins, have shown that food composition and structure have a major impact on their bioaccessibility, transformation, and absorption within the GIT, thereby influencing their bioavailability and bioactivity. This review outlines how insights on the bioavailability of other lipophilic bioactives can be used to facilitate the design of more efficacious and consistent cannabis-enriched products intended for oral consumption. In particular, the importance of food-matrix composition (such as fat type and level) and structural organization (such as fat domain dimensions) are discussed.

First application of atmospheric-pressure chemical ionization gas chromatography tandem mass spectrometry to the determination of cannabinoids in serum

The analysis of cannabinoids in blood samples is still a challenging issue for forensic laboratories, because of the low concentrations to be determined to prove that a person acted under CannabisTherefore, sensitive analytical techniques are required. This study presents the development and validation of a novel APGC-MS/MS method for the simultaneous determination of Δ9-tetrahydrocannabinol (THC), 11-hydroxy- Δ9-THC (THC-OH), 11-nor-9-carboxy- Δ9-THC (THCA), cannabidiol (CBD), cannabidiol acid (CBDA) and cannabigerol (CBG) in human serum. The developed method was fully validated according to international guidelines, with evaluation of selectivity, precision, accuracy, linearity, LODs and LOQs, extraction recovery and matrix effect. The method was linear in the range 0.2-25 ng/mL for THC, THC-OH, CBD and CBG, while for THCA and CBDA linearity was assessed in the range of 0.8-100 ng/mL and 3-100 ng/mL, respectively. The LOQs were determined in 0.2 ng/mL for THC, 0.4 ng/mL for THC-OH, 0.8 ng/mL for CBD and CBG, 1.6 ng/mL for THCA and 3 ng/mL for CBDA. The method was applied to the analysis of 15 serum samples from DUID cases. To the best of our knowledge, the present work is the first one describing an application of APGC source in the field of forensic toxicology.